

Introducing AliveCor's 6-Lead ECG Innovation

K1000 is the product of more than a decade of technology innovation and expertise.



Built on the clinically validated and proven legacy of KardiaMobile[®] 6L, the world's first FDA-cleared, 6-lead personal ECG, K1000 is designed to meet the unique needs of the biopharma industry and delivers medical-grade accuracy, compliance, and real-time insights. Supporting cardiac safety from Phase I through post-marketing, K1000's reliable, long-trusted solutions address today's ECG monitoring challenges and enable future innovation.



300+

Million ECGs Recorded



250+

Clinical Publications



5+

Million Users Worldwide



Key Features

AI-Powered Data Delivery

Instantly detects seven of the most common heart rhythms and provides InstantQT[®], which displays QT interval measurement in seconds*

Remote Data Capture—Anytime, Anywhere

Capture accurate data in clinic and remotely

Seamless Integration for Comprehensive Analysis

Clinicians can assess over 20 additional heart rhythms for a complete cardiac safety profile

Streamlined, Patient-Centric Design

Noninvasive, portable, self-administered design prioritizes patient comfort while delivering medical-grade accuracy

*QT measurements made using the EK12 ECG algorithm



FDA-cleared,
6-lead device



30-second
results



7 heart rhythms
captured instantly



20 additional heart rhythms
for clinician analysis

Empowering Cardiac Safety Across the Entire Drug Lifecycle

Real-Time Data for Decentralized, Hybrid, and Modern Trials

K1000 empowers onsite and remote flexibility, optimizes workflows, and minimizes delays. Cardiac data is captured and analyzed seamlessly, providing the compliance, adaptability, and actionable insights required for success.

Seamless ECG Data Integration for Comprehensive Analysis

K1000 transforms ECG recordings into fully analyzed reports, supporting accurate assessment and informed decision-making. Seamless integration with CROs, EDCs, and Core Labs streamlines data flow for real-time analysis.

Better Adherence and Retention, in Your Back Pocket

Participants are empowered to manage their own care remotely, minimizing dropout rates. The device expands access in resource-limited areas, and reduces the need for clinic visits—enhancing recruitment and retention.

Data You Need, When You Need it

In addition to instantly displaying QT interval measurement, seven key determinations are displayed in just 30 seconds:

- Atrial Fibrillation (AFib)
- Bradycardia
- Tachycardia
- Normal Sinus Rhythm
- Sinus Rhythm with PVCs
- Sinus Rhythm with SVE
- Sinus Rhythm with Wide QRS

Plus, gain clinician assessment of over 20 additional heart rhythms and arrhythmias—including atrial flutter, ventricular bigeminy/trigeminy, and junctional rhythm.



Delivering Advantages Across Therapeutic Areas

Cardiovascular

Oncology

CNS

GLP-1

Pain Management

Rare Diseases

Infectious Diseases

Pulmonology

Experience the AliveCor Impact

Our multiple device options are custom-integrated to meet specific protocol requirements, ensuring trial flexibility and long-term commercial potential. *Discover more at [alivecor.com/biopharma](https://www.alivecor.com/biopharma).*